CFDE Data Portal | Search LOC105372703

	Label	Description
	LOC105372703 Gene (Entity type)	ENSG00000277270 - uncharacterized LOC105372703
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE198930 prunetin AGS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE102505 tunicamycin 6 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE235701 GSE261434 enasidenib 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 0 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105372703

ENSG00000277270 - uncharacterized LOC105372703

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 5 human dn

A Gene Set from LINCS

GSE198930 prunetin AGS 1 v 0 human dn

A Gene Set from LINCS

GSE199107 tryptophan 4 v 5 human dn

A Gene Set from LINCS

GSE102505 tunicamycin 6 v 3 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human dn

A Gene Set from LINCS

GSE113655 phenol 3 v 2 human dn

A Gene Set from LINCS

GSE235701 GSE261434 enasidenib 2 v 1 human dn

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 0 v 12 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.